T-Gimmune

T-Gimmune is a biotechnology company focused on developing next-generation T-cell receptor (TCR) engineered T-cell therapies for the treatment of solid tumors, with a particular emphasis on liver cancer. The company utilizes a proprietary discovery platform to identify high-affinity, tumor-specific TCRs that can effectively target intracellular antigens. Their lead programs focus on well-validated targets such as Alpha-fetoprotein (AFP) and GPC3 to address the high unmet medical need in hepatocellular carcinoma. By leveraging advanced cell engineering techniques, T-Gimmune aims to overcome the immunosuppressive microenvironment of solid tumors and provide curative options for cancer patients.